Stock Market & Financial Investment News

News Breaks September 21, 2012 10:49 EDT MYL, NVS Mylan launches first generic vesrion of Diovan HCT tablets Mylan (MYL) announced that its subsidiary Mylan Pharmaceuticals has received final approval from the FDA for its Abbreviated New Drug Application for Valsartan and Hydrochlorothiazide Tablets USP, 80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg and 320/25 mg. This product is the generic version of Novartis' (NVS) Diovan HCT Tablets, which are indicated for the treatment of hypertension, to lower blood pressure in patients not adequately controlled with monotherapy or as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals News For MYL;NVS From The Last 14 Days Check below for free stories on MYL;NVS the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 17, 2013 16:20 EDT NVS Novartis drug Afinitor extended time without disease progression in women Subscribe for More Information 14:48 EDT MYL Actavis may bid for Warner Chilcott to ward off takeover, Reuters says Subscribe for More Information 13:56 EDT MYL Actavis may purchase Warner Chilcott as takeover defense, Reuters reports Over past few weeks, Actavis (ACT) has "spurned approaches" from Valeant (VRX) and Mylan (MYL), and has instead pursued a bid for Warner Chilcott (WCRX), according to Reuters, citing people familiar with the situation. 07:31 EDT MYL Mylan launches generic Tricor tablets Subscribe for More Information May 16, 2013 08:11 EDT NVS Novartis says no intention of pursuing Actavis, Bloomberg reports Subscribe for More Information May 15, 2013 19:37 EDT MYL, NVS Novartis weighing Actavis bid, WSJ reports Subscribe for More Information 18:17 EDT NVS Novartis weighs possible bid for Actavis, DJ reports Subscribe for More Information 17:36 EDT MYL Paulson gives quarterly update on stakes Subscribe for More Information 11:42 EDT MYL Mylan launches generic Zomig tablets Subscribe for More Information 07:03 EDT MYL Mylan highly unlikely to acquire Actavis, says Barclays Subscribe for More Information May 14, 2013 13:55 EDT MYL Actavis weighing over $5B bid for Warner Chilcott, snubbed Mylan, Bloomberg says Subscribe for More Information 13:22 EDT MYL Actavis turned down $15B takeover bid from Mylan, Bloomberg reports Subscribe for More Information May 10, 2013 10:00 EDT MYL On The Fly: Analyst Initiation Summary Today's noteworthy initiations include: 3D Systems (DDD) initiated with a Buy at Janney Capital... Actavis (ACT) initiated with an Outperform at BMO Capital... Allergan (AGN) initiated with an Outperform at BMO Capital... Emeritus (ESC) initiated with an Outperform at Wells Fargo... Ensign Group (ENSG) initiated with a Market Perform at Wells Fargo... Forest Labs (FRX) initiated with an Underperform at BMO Capital... J2 Global (JCOM) initiated with an Outperform at Wedbush... Mylan (MYL) initiated with an Underperform at BMO Capital... Splunk (SPLK) initiated with a Market Perform at FBR Capital... Teva (TEVA) initiated with an Outperform at BMO Capital... Workday (WDAY) initiated with an Outperform at Oppenheimer... Nuance (NUAN) initiated with an Outperform at Wedbush... Demandware (DWRE) initiated with an Outperform at Wedbush... Synchronoss (SNCR) initiated with an Outperform at Wedbush... Trius Therapeutics (TSRX) initiated with a Buy at Guggenheim... Proto Labs (PRLB) initiated with a Buy at Janney Capital... Stratasys (SSYS) initiated with a Buy at Janney Capital. 05:42 EDT NVS Novartis drug Ilaris approved by FDA Subscribe for More Information May 9, 2013 16:34 EDT MYL Mylan initiated with an Underperform at BMO Capital Subscribe for More Information May 6, 2013 16:23 EDT NVS Array to start first company-led Phase 3 trial with MEK162 Array (ARRY) announced the planned start of its first company-led Phase 3 trial with MEK162 in low-grade serous ovarian cancer. This is the third MEK162 pivotal trial that is expected to initiate in 2013 and one of five pivotal trials Array expects to begin in 2013 on Array-invented products. Novartis (NVS), who is co-developing MEK162 with Array, previously stated that Phase 3 trials in NRAS-mutant melanoma and BRAF-mutant melanoma are expected to start this year and AstraZeneca has announced its plans to initiate two registration trials with selumetinib, a MEK inhibitor invente (AZN) d by Array, in KRAS-mutant non-small cell lung cancer and in thyroid cancer. Array also recently released initial data on its wholly-owned hematology drug, ARRY-520, from a combination trial with VelcadeŽ (bortezomib) in patients with relapsed or refractory multiple myeloma (MM), showing that the drug was generally well-tolerated and showed initial signs of activity in this heavily pretreated population. Sign up for a free trial to see the rest of the stories you've been missing.